England Approves New Stomach Cancer Treatment in 17 Days

England just made history by approving a promising new stomach cancer treatment in just 17 days, giving hope to thousands of patients facing one of medicine's toughest battles.

The National Institute for Health and Care Excellence (NICE) has approved durvalumab for adults with stomach cancer that hasn't spread extensively and can be surgically removed. The treatment works by blocking a protein called PD-L1, which essentially unmasks cancer cells so the immune system can find and destroy them.

The numbers tell a powerful story. In clinical trials, 67% of patients using durvalumab with chemotherapy were event-free after two years, compared to 59% with chemotherapy alone. Overall survival rates also jumped, with 76% of durvalumab patients alive after two years versus 70% in the control group.

These improvements matter deeply because stomach cancer is particularly aggressive. Currently, the cancer returns in many patients after surgery, and only about half survive five years after diagnosis. Most people aren't diagnosed until the disease has already advanced.

NICE used a special "light touch" approval process to fast-track durvalumab, cutting through red tape to get the treatment to patients faster. The drug received the green light just over two weeks after the UK medicines regulator authorized it.

More than 1,500 people in England will benefit from the treatment each year. Patients receive durvalumab through an IV infusion every four weeks, combined with standard chemotherapy drugs.

The Ripple Effect

This approval represents the first major breakthrough in curable stomach cancer treatment in nearly a decade. Sheena Dewan from Stomach Cancer UK says it offers families "a meaningful opportunity for more time with loved ones, more time at work and more time to live well beyond treatment."

The fast approval process shows how regulatory agencies can adapt when patients need urgent solutions. By streamlining reviews without compromising safety, NICE demonstrated that speed and thoroughness can coexist in medical approvals.

Helen Knight, director of medicines evaluation at NICE, emphasized the urgency: "There is an urgent need for treatments like durvalumab that meaningfully extend both the length and quality of patients' lives."

For patients who have endured the constant fear of cancer returning after grueling surgery and treatment, this breakthrough offers something invaluable: hope backed by science.